Difference between revisions of "Prostate-specific antigen"

From Libre Pathology
Jump to navigation Jump to search
Line 14: Line 14:
Better predictor than (unadjusted) serum PSA for:
Better predictor than (unadjusted) serum PSA for:
*Gleason score upgrading on [[prostatectomy]].<ref>{{cite journal |author=Sfoungaristos S, Katafigiotis I, Perimenis P |title=The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era |journal=Can Urol Assoc J |volume=7 |issue=11-12 |pages=E722–7 |year=2013 |pmid=24282465 |pmc=3840515 |doi=10.5489/cuaj.374 |url=}}</ref>
*Gleason score upgrading on [[prostatectomy]].<ref>{{cite journal |author=Sfoungaristos S, Katafigiotis I, Perimenis P |title=The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era |journal=Can Urol Assoc J |volume=7 |issue=11-12 |pages=E722–7 |year=2013 |pmid=24282465 |pmc=3840515 |doi=10.5489/cuaj.374 |url=}}</ref>
*BPH versus cancer.<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref>
*BPH versus cancer.<ref name=pmid1371554>{{cite journal |author=Benson MC, Whang IS, Pantuck A, ''et al.'' |title=Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer |journal=J. Urol. |volume=147 |issue=3 Pt 2 |pages=815–6 |year=1992 |month=March |pmid=1371554 |doi= |url=}}</ref><ref>{{cite journal |author=Verma A, St Onge J, Dhillon K, Chorneyko A |title=PSA density improves prediction of prostate cancer |journal=Can J Urol |volume=21 |issue=3 |pages=7312–21 |year=2014 |month=June |pmid=24978363 |doi= |url=}}</ref>


====A forumla for PSAD====
====A forumla for PSAD====

Revision as of 04:23, 30 July 2014

Prostate specific antigen, abbreviated PSA, is marker that is quite specific for the prostate.

General

  • Quantity in the serum used to screen for prostate cancer.
  • PSA immunostain useful for classifying a carcinoma as prostate carcinoma.

Serum PSA

  • Normal - typically < 4.0 ng/mL.
  • Increases with age.[1]

Prostate specific antigen density

  • Abbreviated PSAD.

Better predictor than (unadjusted) serum PSA for:

A forumla for PSAD

  • Benson et al.:[3]
  • Where:
D1, D2, D3 are the major axes.

Note:

  • The volume of an ellipsoid is:

See also

References

  1. Ku JH, Ahn JO, Lee CH, et al. (September 2002). "Distribution of serum prostate-specific antigen in healthy Korean men: influence of ethnicity". Urology 60 (3): 475–9. PMID 12350489.
  2. Sfoungaristos S, Katafigiotis I, Perimenis P (2013). "The role of PSA density to predict a pathological tumour upgrade between needle biopsy and radical prostatectomy for low risk clinical prostate cancer in the modified Gleason system era". Can Urol Assoc J 7 (11-12): E722–7. doi:10.5489/cuaj.374. PMC 3840515. PMID 24282465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840515/.
  3. 3.0 3.1 Benson MC, Whang IS, Pantuck A, et al. (March 1992). "Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer". J. Urol. 147 (3 Pt 2): 815–6. PMID 1371554.
  4. Verma A, St Onge J, Dhillon K, Chorneyko A (June 2014). "PSA density improves prediction of prostate cancer". Can J Urol 21 (3): 7312–21. PMID 24978363.